Beraprost 314d Added on to Tyvaso 2018-09-07T13:57:21+00:00

Clinical Trials

August 15, 2016

A multicenter, double-blind, randomized, placebo-controlled, Phase 3 study to assess the efficacy and safety of oral BPS-314d-MR added on to treprostinil, inhaled (Tyvaso) in subjects with pulmonary hypertension

  • Study Sponsor: Lung Biotechnology
  • Institution: Lung Biotechnology, PBC
  • Start Date: June 15, 2013
  • End Date: Active but not recruiting
  • Design: Placebo-controlled, Background treatment allowed
  • Age range (years): from 18 to 80 (inclusive)
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • Heritable – APAH
    • Toxic – APAH
    • HIV – APAH
  • Study Duration for individual patient: Indefinite duration
  • Contact: www.beatclinicaltrial.com
  • Listing on clinicaltrials.gov